---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-102611"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2026-09-23T20:01:32+00:00"
generated_at: "2026-09-23T20:02:25.191400+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Longeveron's ELPIS II Phase 2b misses primary endpoint; strategic review initiated

## Summary
- ELPIS II missed primary endpoint: RVEF change from baseline -0.7 pp (95% CI -7.3 to 5.9, p=0.8336) in ITT.
- Exploratory: no deaths in laromestrocel arm vs 1 control at 12 months; transplant-free survival 1 vs 2 events.
- MACE ~31% fewer (12 vs 19 events) but not statistically significant; no new safety signals across 644 patients.
- Company to explore all options to maximize shareholder value, engaging an investment bank and cost containment.
- Longevity/frailty: Phase 2b data published in Cell Stem Cell Feb 2026; $1M XPRIZE Milestone 2 Award, up to $81M grand prize.

## SEC filing metadata
- accession: 0001213900-26-102611
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2026-09-23T20:01:32+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/0001213900-26-102611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390026102611/ea0306147-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-102611
- JSON: https://secwatch.observer/filing/0001213900-26-102611.json
- Plain text: https://secwatch.observer/filing/0001213900-26-102611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.